<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100462</url>
  </required_header>
  <id_info>
    <org_study_id>13-16785</org_study_id>
    <nct_id>NCT02100462</nct_id>
  </id_info>
  <brief_title>Chlorthalidone and HCTZ Impacts on Platelet Activation</brief_title>
  <official_title>Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dialysis Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double-blinded, three-period crossover study of platelet
      activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone
      (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is
      that CTD has different effects on platelet activation and aggregation than HCTZ.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean fluorescence intensity of PAC-1</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary endpoint for this study will be the change in mean fluorescence intensity (MFI) of the platelet activation marker PAC-1 due to HCTZ, CTD, and aspirin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CD62P expression</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in platelet expression of CD62P (p-selectin) in response to CTD, HCTZ, and ASA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet aggregation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in platelet aggregation measured by flow cytometry in response to CTD, HCTZ, and ASA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Chlorthalidone 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorthalidone 12.5 mg by mouth once daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 81 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81 mg by mouth once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone 12.5 mg</intervention_name>
    <arm_group_label>Chlorthalidone 12.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide 25 mg</intervention_name>
    <arm_group_label>Hydrochlorothiazide 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <arm_group_label>Aspirin 81 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age 19 or older

          -  Not currently taking any routinely scheduled prescription or over the counter
             medications or herbal supplements

          -  No use of aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, dipyridamole, NSAID
             medications, or herbal supplements within the previous 7 days and able to refrain from
             use during the study period

          -  Systolic blood pressure &gt; 110 mmHg and diastolic blood pressure &gt; 60 mmHg

          -  Non-smoker

        Exclusion Criteria:

          -  Previous adverse reaction or allergy to HCTZ, CTD, or ASA

          -  Severe sulfonamide hypersensitivity (anaphylaxis or Stevens-Johnson syndrome)

          -  Diagnosis of any chronic disease or condition

          -  History of gout or hyperuricemia

          -  History of pancreatitis

          -  History of systemic lupus erythematosus (SLE)

          -  History of hypokalemia requiring treatment

          -  Pregnant or planning to become pregnant during the study period

          -  Breastfeeding

          -  History of hypotension

          -  History of gastrointestinal bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalid Bashir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandy Byers, RN</last_name>
    <phone>402-280-4961</phone>
    <email>sandrabyers@creighton.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Nubel, BS</last_name>
    <phone>402-280-4032</phone>
    <email>carolinenubel@creighton.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68178</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Byers, RN</last_name>
      <phone>402-280-4961</phone>
      <email>sandrabyers@creighton.edu</email>
    </contact>
    <investigator>
      <last_name>Tammy L Burns, PharmD, BCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khalid Bashir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael White, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel E Hilleman, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkata M Alla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkata Andukuri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Platelet activation</keyword>
  <keyword>Platelet aggregation</keyword>
  <keyword>Chlorthalidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

